SynthesisFrontiers in oncology2025
Advances on cancer vaccine trials registered in China and the USA in 2014-2024.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mapping the Evolutionary Landscape of Solid Tumor Immunotherapy: A Quarter-Century Bibliometric Analysis of the Title-Defined Core Literature (2000-2025).International journal of medical sciences · 2026Article
- Current status of vaccine clinical trials registered on China's Drug Trial Registration and information disclosure platform, 2013-2024.Frontiers in public health · 2026Article
- Current Progress of Cell Therapy Clinical Trials in China in 2014-2024.BioMed research international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The clinical trials of cancer vaccine in China and the USA were summarized and compared over the past decade, thus putting forward suggestions for future clinical development in this field. Methods: Mainly based on the Centre for Drug Evaluation of China National Medical Products Administration website (NMPA) and ClinicalTrials.gov, a list and detailed information of cancer vaccine trials in China and the USA were acquired, respectively. Vaccines licensed for use in China and the USA were acquired from NMPA and Food and Drug Administration (FDA), respectively. Subgroup comparison in terms of initiated trials was conducted between the two countries. Results: In 2014-2024, there were 89 trials and 757 trials of cancer vaccine registered in China and the USA, respectively. In terms of the phase distribution, there were less phase I (28.1% vs 52.1%), phase II (15.7% vs 36.3%), and more phase III (40.5% vs 7.9%), phase IV (15.7% vs 3.7%) trials in China compared with those in the USA (χ Conclusion: Both China and the USA have made great progress in cancer vaccines in 2014-2024. The difference and gap between China and the USA highlight that more efforts should be paid on innovative cancer vaccines in China. Perhaps in the future, we can pay more attention to increasing the investment in drug research and development, carrying out more global multi-center clinical trials and participating more in trials led by top 20 pharmaceutical companies worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.